Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia - PubMed (original) (raw)
. 1999 Feb 15;59(4):793-7.
Affiliations
- PMID: 10029064
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia
M Esteller et al. Cancer Res. 1999.
Abstract
The DNA repair protein O6-methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the O6 position of guanine. MGMT expression is decreased in some tumor tissues, and lack of activity has been observed in some cell lines. Loss of expression is rarely due to deletion, mutation, or rearrangement of the MGMT gene, but methylation of discrete regions of the CpG island of MGMT has been associated with the silencing of the gene in cell lines. We used methylation-specific PCR to study the promoter methylation of the MGMT gene. All normal tissues and expressing cancer cell lines were unmethylated, whereas nonexpressing cancer cell lines were methylated. Among the more than 500 primary human tumors examined, MGMT hypermethylation was present in a subset of specific types of cancer. In gliomas and colorectal carcinomas, aberrant methylation was detected in 40% of the tumors, whereas in non-small cell lung carcinomas, lymphomas, and head and neck carcinomas, this alteration was found in 25% of the tumors. MGMT methylation was found rarely or not at all in other tumor types. We also analyzed MGMT expression by immunohistochemistry in relation to the methylation status in 31 primary tumors. The presence of aberrant hypermethylation was associated with loss of MGMT protein, in contrast to retention of protein in the majority of tumors without aberrant hypermethylation. Our results suggest that epigenetic inactivation of MGMT plays an important role in primary human neoplasia.
Similar articles
- Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.
Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG. Esteller M, et al. Cancer Res. 2000 May 1;60(9):2368-71. Cancer Res. 2000. PMID: 10811111 - Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma.
Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Zhang L, et al. Carcinogenesis. 2003 Jun;24(6):1039-44. doi: 10.1093/carcin/bgg062. Epub 2003 Apr 24. Carcinogenesis. 2003. PMID: 12807758 - O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA. Wolf P, et al. Cancer Res. 2001 Nov 15;61(22):8113-7. Cancer Res. 2001. PMID: 11719438 - Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
Esteller M, Herman JG. Esteller M, et al. Oncogene. 2004 Jan 8;23(1):1-8. doi: 10.1038/sj.onc.1207316. Oncogene. 2004. PMID: 14712205 Review. - MGMT hypermethylation: a prognostic foe, a predictive friend.
Jacinto FV, Esteller M. Jacinto FV, et al. DNA Repair (Amst). 2007 Aug 1;6(8):1155-60. doi: 10.1016/j.dnarep.2007.03.013. Epub 2007 May 7. DNA Repair (Amst). 2007. PMID: 17482895 Review.
Cited by
- Upregulation of SATB1 is associated with the development and progression of glioma.
Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC. Chu SH, et al. J Transl Med. 2012 Jul 28;10:149. doi: 10.1186/1479-5876-10-149. J Transl Med. 2012. PMID: 22839214 Free PMC article. - Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Kurdi M, Butt NS, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, Saeedi R, Dallol A, Mohamed F, Bari MO, Samkari A, Lary AI, Alkhayyat S. Kurdi M, et al. J Neurooncol. 2021 May;152(3):541-549. doi: 10.1007/s11060-021-03723-9. Epub 2021 Mar 4. J Neurooncol. 2021. PMID: 33661424 Free PMC article. - Epigenetics of kidney cancer and bladder cancer.
Hoffman AM, Cairns P. Hoffman AM, et al. Epigenomics. 2011 Feb;3(1):19-34. doi: 10.2217/epi.10.64. Epigenomics. 2011. PMID: 22126150 Free PMC article. Review. - Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D'Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C. Ceccato F, et al. J Neurooncol. 2015 Mar;122(1):189-96. doi: 10.1007/s11060-014-1702-0. Epub 2015 Jan 3. J Neurooncol. 2015. PMID: 25555563 - The Role of Stem Cell DNA Methylation in Colorectal Carcinogenesis.
Song L, Li Y. Song L, et al. Stem Cell Rev Rep. 2016 Oct;12(5):573-583. doi: 10.1007/s12015-016-9672-6. Stem Cell Rev Rep. 2016. PMID: 27402365 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials